187 related articles for article (PubMed ID: 36122509)
1. An insight into the discovery, clinical studies, compositions, and patents of macozinone: A drug targeting the DprE1 enzyme of Mycobacterium tuberculosis.
Imran M; Khan SA; Asdaq SMB; Almehmadi M; Abdulaziz O; Kamal M; Alshammari MK; Alsubaihi LI; Hussain KH; Alharbi AS; Alzahrani AK
J Infect Public Health; 2022 Oct; 15(10):1097-1107. PubMed ID: 36122509
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from Mycobacterium tuberculosis.
Piton J; Vocat A; Lupien A; Foo CS; Riabova O; Makarov V; Cole ST
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012754
[TBL] [Abstract][Full Text] [Related]
3. Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).
Lupien A; Vocat A; Foo CS; Blattes E; Gillon JY; Makarov V; Cole ST
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126954
[TBL] [Abstract][Full Text] [Related]
4. Synthetic molecules as DprE1 inhibitors: A patent review.
Imran M; A S A; Thabet HK; Abida ; Afroz Bakht M
Expert Opin Ther Pat; 2021 Aug; 31(8):759-772. PubMed ID: 33709862
[TBL] [Abstract][Full Text] [Related]
5. [The main results of clinical trials of the efficacy, safety and pharmacokinetics of the perspective anti-tuberculosis drug makozinone (PBTZ169)].
Mariandyshev AO; Khokhlov AL; Smerdin SV; Shcherbakova VS; Igumnova OV; Ozerova IV; Bolgarina AA; Nikitina NA
Ter Arkh; 2020 Apr; 92(3):61-72. PubMed ID: 32598795
[TBL] [Abstract][Full Text] [Related]
6. Identification of Mutations Associated With Macozinone-Resistant in Mycobacterium Tuberculosis.
Chen X; Li Y; Wang B; Lu Y
Curr Microbiol; 2022 May; 79(7):205. PubMed ID: 35616769
[TBL] [Abstract][Full Text] [Related]
7. QcrB inhibition as a potential approach for the treatment of tuberculosis: A review of recent developments, patents, and future directions.
Imran M; Abida ; Alotaibi NM; Thabet HK; Alruwaili JA; Asdaq SMB; Eltaib L; Alshehri A; Alsaiari AA; Almehmadi M; Alshammari ABH; Alshammari AM
J Infect Public Health; 2023 Jun; 16(6):928-937. PubMed ID: 37086552
[TBL] [Abstract][Full Text] [Related]
8. Antituberculosis Macozinone Extended-Release Tablets To Enhance Bioavailability: a Pilot Pharmacokinetic Study in Beagle Dogs.
Koryakova A; Shcherbakova V; Riabova O; Kazaishvili Y; Bolgarin R; Makarov V
Microbiol Spectr; 2023 Feb; 11(1):e0232722. PubMed ID: 36507624
[TBL] [Abstract][Full Text] [Related]
9. Insights into development of Decaprenyl-phosphoryl-β-D-ribose 2'-epimerase (DprE1) inhibitors as antitubercular agents: A state of the art review.
Bonde C; Gawad J; Bonde S
Indian J Tuberc; 2022 Oct; 69(4):404-420. PubMed ID: 36460369
[TBL] [Abstract][Full Text] [Related]
10. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
11. [Effect of physicochemical properties on the pharmacokinetic parameters of the new representative of benzothiazinones antituberculosis drug macozinonе].
Khokhlov AL; Mariandyshev AO; Shcherbakova VS; Ozerova IV; Kazaishvili YG; Igumnova OV; Bolgarina AA; Rudoy BA
Ter Arkh; 2020 Dec; 92(12):165-171. PubMed ID: 33720590
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of macozinone in mice with genetically diverse susceptibility to Mycobacterium tuberculosis infection.
Nikonenko B; Logunova N; Egorova A; Kapina M; Sterzhanova N; Bocharova I; Kondratieva E; Riabova O; Semyonova L; Makarov V;
Microbes Infect; 2024 Jun; ():105376. PubMed ID: 38852904
[TBL] [Abstract][Full Text] [Related]
13. Towards a new combination therapy for tuberculosis with next generation benzothiazinones.
Makarov V; Lechartier B; Zhang M; Neres J; van der Sar AM; Raadsen SA; Hartkoorn RC; Ryabova OB; Vocat A; Decosterd LA; Widmer N; Buclin T; Bitter W; Andries K; Pojer F; Dyson PJ; Cole ST
EMBO Mol Med; 2014 Mar; 6(3):372-83. PubMed ID: 24500695
[TBL] [Abstract][Full Text] [Related]
14. Structure based pharmacophore modelling approach for the design of azaindole derivatives as DprE1 inhibitors for tuberculosis.
Kb S; Kumari A; Shetty D; Fernandes E; Dv C; Jays J; Murahari M
J Mol Graph Model; 2020 Dec; 101():107718. PubMed ID: 32949960
[TBL] [Abstract][Full Text] [Related]
15. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
16. Current Affairs, Future Perspectives of Tuberculosis and Antitubercular Agents.
Gawad J; Bonde C
Indian J Tuberc; 2018 Jan; 65(1):15-22. PubMed ID: 29332642
[TBL] [Abstract][Full Text] [Related]
17. MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature.
Imran M; Arora MK; Chaudhary A; Khan SA; Kamal M; Alshammari MM; Alharbi RM; Althomali NA; Alzimam IM; Alshammari AA; Alharbi BH; Alshengeti A; Alsaleh AA; Alqahtani SA; Rabaan AA
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359313
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the development of DprE1 inhibitors using AI/CADD approaches.
Chen K; Xu R; Hu X; Li D; Hou T; Kang Y
Drug Discov Today; 2024 Jun; 29(6):103987. PubMed ID: 38670256
[TBL] [Abstract][Full Text] [Related]
19. Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection.
Dzinamarira T; Almehmadi M; Alsaiari AA; Allahyani M; Aljuaid A; Alsharif A; Khan A; Kamal M; Rabaan AA; Alfaraj AH; AlShehail BM; Alotaibi N; AlShehail SM; Imran M
Medicina (Kaunas); 2023 May; 59(6):. PubMed ID: 37374245
[TBL] [Abstract][Full Text] [Related]
20. Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.
Chikhale RV; Barmade MA; Murumkar PR; Yadav MR
J Med Chem; 2018 Oct; 61(19):8563-8593. PubMed ID: 29851474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
